| Characteristic . | ZH33 . | ZG66 . | ZJ31 . | ZJ38 . | ZH19 . | ZK22 . | ZL40 . |
|---|---|---|---|---|---|---|---|
| CD34+ transplant dose (millions) | 32 | 48 | 23 | 13 | 48 | 82 | 57 |
| CD34+ transplant dose/kg (millions) | 6.9 | 8.5 | 4.1 | 2.3 | 7.1 | 7.2 | 8.1 |
| GFP+ infused cells (%) | 35 | 35 | 35 | 19 | 23 | 31 | 22.5 |
| Infused GFP+ cells (millions) | 11.1 | 16.7 | 8.0 | 2.5 | 11.0 | 25.2 | 12.8 |
| Follow-up time points (mo) | 5, 9, 15.5, 46 | 7, 12.5 | 3.5, 8.5, 18, 25.5 | 5, 9 | 6, 9, 45.5 | 3.5, 11.5 | 4 |
| Characteristic . | ZH33 . | ZG66 . | ZJ31 . | ZJ38 . | ZH19 . | ZK22 . | ZL40 . |
|---|---|---|---|---|---|---|---|
| CD34+ transplant dose (millions) | 32 | 48 | 23 | 13 | 48 | 82 | 57 |
| CD34+ transplant dose/kg (millions) | 6.9 | 8.5 | 4.1 | 2.3 | 7.1 | 7.2 | 8.1 |
| GFP+ infused cells (%) | 35 | 35 | 35 | 19 | 23 | 31 | 22.5 |
| Infused GFP+ cells (millions) | 11.1 | 16.7 | 8.0 | 2.5 | 11.0 | 25.2 | 12.8 |
| Follow-up time points (mo) | 5, 9, 15.5, 46 | 7, 12.5 | 3.5, 8.5, 18, 25.5 | 5, 9 | 6, 9, 45.5 | 3.5, 11.5 | 4 |
ZH33 received G-CSF+ stem cell factor mobilization for 4 d at 6.5 and 26 mo posttransplantation.